Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Assets (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Assets readings, the most recent being $1.1 billion for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 21.49% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 21.49%, and an annual FY2025 reading of $1.1 billion, up 21.49% over the prior year.
  • Assets hit $1.1 billion in Q4 2025 for Apellis Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • The five-year high for Assets was $1.1 billion in Q1 2022, with the low at $525.7 million in Q3 2021.
  • Median Assets over the past 5 years was $877.3 million (2021), compared with a mean of $874.3 million.
  • The sharpest move saw Assets crashed 31.58% in 2021, then skyrocketed 66.05% in 2022.
  • Year by year, Assets stood at $881.8 million in 2021, then dropped by 13.78% to $760.2 million in 2022, then grew by 3.75% to $788.7 million in 2023, then rose by 12.21% to $885.1 million in 2024, then increased by 21.49% to $1.1 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $1.1 billion, $1.1 billion, and $821.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.